Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis

Folia Histochemica et Cytobiologica

Volumn 48, Issue 4, 2010, Pages 603-610

  Donica, H ^a   Malecha Jedraszek, A ^a   Stroslawska E ^b   Burska, A ^a   Szubstarski, F ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Oncological Centre of Lublin Region   (Poland)

Author keywords

Chromogranin A (CgA); Neuroendocrine tumour (NET)

Indexed keywords

CHROMOGRANIN A; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; SYMPTOM; TUMOR CLASSIFICATION;

EID: 79958033227     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.2478/v10042-010-0088-x     Document Type: Article

References (33)

1. Ardill J, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endoc-Relat Cancer. 2003;10:459-462.
2. Feldman S, Eiden E. The Chromogranis: Their Roles In Secretion from Neuroendocrine Cells and as Markers from Neuroendocrine Neoplasia. Endocrine Pathology. 2003;14:3-23.
3. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J. 1989;262:1-13.
4. Taupenot L, Harper KL, O'Connor DT. The chromogranin/secretogranin family. N Eng J Med. 2003;348:1134-1149.
5. Zatelli MC, Torta M, Leon A et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr-Relat Cancer. 2007;14:473-482.
6. Campana D, Nori F, Piscitelli L et al. Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?. J Clin Oncol. 2007;25:1967-1973.
7. Giovanella L. Chromogranin A a circulating neuroendocrine marker. Cis Bio. 2003; 1-46.
8. Zdrojewicz Z, Stadnik E, Rubinsztain R. Chromogranina Abudowa, działanie, znaczenie kliniczne. Problemy Terapii Monitorowanej. 1999;2:84-90.
9. Eriksson B, Öberg K, Stridsberg M. Tumor Markers in Neuroendocrine Tumors. Digestion. 2000;62:33-38.
10. Nehar D, Lombard-Bohas C, Olivieri S et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol. 2004;60:644-652.
11. Plockinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus treatment on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394-424.
12. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med. 1998;76:413-420.
13. Vinik A. Carcinoid tumors. Diffuse Hormonal Systems. Endotext.com. 2004;1-124.
14. Bajetta E, Ferrari L, Martinetti A et al. Chromogranin A, neuron-specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865.
15. Tomassetti P, Migliori M, Lalli S et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12:S95-S99.
16. Kölby L, Bernhardt P, Swärd Ch et al. Chromogranina A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004;120:269-273.
17. Baudin E, Bidart JM, Bachelot A et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol. 2001, 12, S79-S82.
18. Nobels FRE, Kwekkeboom D, Bouillon R et al. Chromogranin A: its clinical value as marker of neuroendocrine tumors. Eur J Clin Invest. 1998;24:431-438.
19. Caplin ME, Wiedenmann B. The management of patients with neuroendocrine tumours. Endoc-Relat Cancer. 2003;10:425-426.
20. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511.
21. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
22. Tomassetti P, Migliori M, Simoni P et al. Diagnostic value of plasma Chromogranin A in neuroendocrine tumors. Eur J Gastroenterol Hepatol. 2001;13:55-58.
23. Perri P, Cavaliere F, Botti C et al. Epidemiology of gastroenteropancreatic neuroendocrine tumors. W: Update in Neuroendocrinology. Baldelli R, Casanueva FF, Tamburrano G. Udine Centro UD. 2004;483-512.
24. Janson ET, Holmberg L, Stridsberg M et al. Carcinoid tumors. Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8:685-690.
25. Nobels FRE, Kwekkeboom DJ, Coopmans W et al. Chromogranin Aas serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and and the α-subunit secreting of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622-2628.
26. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13-27.
27. Rindi G. Klöppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology. 2004;80:12-15.
28. Seregni E, Ferrari L, Bajetta E et al. Clinical significance of blood CgA measurement in endocrine tumors. Ann Oncol. 2001;12:S69-S72.
29. Stivanello M, Berruti A, Torta M et al. Circulating Chromogranin A in the assessment of patients with neuroendocrine tumors. A single institution experience. Ann Oncol. 2001;12:573-577.
30. Peracchi M, Conte D, Gebbia C et al. Plasma Chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol. 2003;148:39-43.
31. Cimitan M, Buonadonna A, Cannizzaro R et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol. 2003;14:1135-1141.
32. Schürmann G, Raeth U, Wiedenmann B et al. Serum Chromogranin A in the diagnosis and the follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J Surg. 1992;16:697-702.
33. Stridsberg M, Eriksson B, Oberg K et al. A comparison between three commercial kits for Chromogranin A measurements. J Endocrinol. 2003;177:337-341.